Top Cheapest Companies For 2015

Top Cheapest Companies For 2015: Prometheus RxDx Corp (RXDX)

Prometheus RxDx Corp., incorporated in June 2009, is a wholly owned subsidiary of Prometheus Laboratories Inc. The Company is engaged in the development and commercialization of pharmaceutical and diagnostic products that enable physicians to provide individualized patient care. It focuses on the detection, diagnosis and treatment of disorders within the fields of gastroenterology and oncology. It operates in two segments: the pharmaceutical products segment that markets and sells prescription drugs, and the diagnostic testing services segment, which includes specific immunoassays to detect and differentiate diseases, pharmacogenetic testing and drug metabolite monitoring. The pharmaceutical products for gastrointestinal diseases and disorders includes ENTOCORT EC (budesonide) Capsules, which is indicated for the treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon, and LOTRONEX (alosetron hydrochloride) Tablets, for use in female patients with severe diarrhea-predominant irritable bowel syndrome (IBS).

Gastroenterology Pharmaceutical Products

The pharmaceutical products for gastrointestinal diseases and disorders include Entocort EC for the treatment of mild to moderate active Crohn's disease involving the ileum and/or ascending colon and Lotronex for treatment of a subset of women with severe diarrhea-predominant IBS. The Company sells but does not market, several other pharmaceuticals, including Imuran, Helidac Therapy, and Ridaura, in addition to a number of other diagnostic tests. It also manufactures a generic mercaptopurine product, which is sold through a third-party distributor. It only offers pharmaceutical products in the United States. It began selling Proleukin in February 2010 under an exclusive distribution and promotion agreement with Novartis. Proleukin is ! a recombinant human interleukin-2 for treatment in adults with metastatic renal cell carcinom a and metastatic melanoma. Proleukin therapy is a form of im! munotherapy that uses the body's natural immune system to fight cancer. In December 2010, it signed an agreement with ThePharmaNetwork, LLC, to sell Trandate and Zyloprim.

Entocort EC is the Food and Drug Association- approved drug indicated for the induction and maintenance of clinical remission in mild to moderate active Crohn's disease involving the ileum and/or the ascending colon. Entocort EC consists of an encapsulated formulation of budesonide granules, a glucocorticosteroid. Entocort EC is designed to release primarily in the ileum and/or the ascending colon, so that as little as 10% of the drug enters systemic circulation. Entocort EC may benefit patients by reducing glucocorticosteroid-related side effects. Lotronex is indicated for use only in women with severe diarrhea-predominant IBS who have not responded adequately to conventional therapy, whose IBS symptoms are chronic, and who have had other gastrointestinal medical conditions ruled out.

Imuran is indicated for adjunctive use in the prevention of rejection in kidney transplants and in the management of active rheumatoid arthritis. Although Imuran is not indicated for the treatment of IBD and the Company does not promote it for that indication, physicians often prescribe it for various forms of IBD, including Crohn's disease and ulcerative colitis, as well as other autoimmune disorders. Imuran is prescribed primarily by gastroenterologists, transplant surgeons, nephrologists, rheumatologists and internal medicine specialists. Helidac Therapy (Hediac), when taken with a hydrogen (H2 ) antagonist, is indicated for the eradication of Helicobacter pylori, or H. pylori, bacteria, which causes peptic ulcers, and for patients with duodenal ulcer disease. Ridaura is approved for the treatment of active classical or definite rheumatoid arthritis in adults. R! idaura is! the oral formulation of a gold salt available for the treatment of rheumatoid arthritis for patients who have not responded adequately to one or mor! e non-ste! roidal anti-inflammatory drugs. Mercaptopurine is approved for maintenance for acute lymphatic leukemia as part of a combination regimen and, although it is not indicated for the treatment of certain gastrointestinal diseases and it does not promote it for those indications, physicians often prescribe it for various forms of IBD, including Crohn's disease and ulcerative colitis.

Trandate is approved for the management of high blood pressure, or hypertension. Trandate can be used alone or in combination with other anti-hypertensive agents, particularly thiazide and loop diuretics. Trandate is typically prescribed by cardiologists, family practitioners and internists. Trandate competes both with generics and many other drugs used to treat hypertension. In December 2010, the Company signed an agreement with ThePharmaNetwork, LLC, to sell Trandate. Zyloprim reduces serum and uric acid levels and is approved for the management of patients with gout, patients receiv ing certain types of chemotherapy to leukemia, lymphoma and other cancers, and patients with kidney or urinary stones. Zyloprim is prescribed by orthopedic specialists, rheumatologists, podiatrists, nephrologists and family practitioners.

Gastroenterology Diagnostic Testing Services

The diagnostic testing services are designed to aid physicians in making diagnoses with non-invasive testing and to assist them in determining therapy treatment and management, thereby helping a physician customize treatment to an individual patient. The Company performs all its diagnostic testing services in its laboratory located in San Diego, California. During the year ended December 31, 2010, it launched PROMETHEUS Crohn's Prognostic, the serogenetic prognostic test for Crohn's disease. The Company offers three celiac tests to physicians, including antib! ody tests! , a genetics test and a panel that combines both the antibody and genetics tests.

The Company competes with Quest Diagnostics Incorporated and La! boratory ! Corporation of America Holdings

Advisors' Opinion:

• [By James E. Brumley]

  Quick - what do CytRx Corporation (NASDAQ:CYTR) and Ignyta Inc. (NASDAQ:RXDX) have in common? Yes, they're both biotech stocks, but that's not the absolute best answer right now. The most meaningful common element between RXDX and CYTR right now is, each is on the verge of a big technical breakout and deserves a spot on your watchlist. Here's a closer look at each. 

source from Top Stocks For 2015:http://www.topstocksblog.com/top-cheapest-companies-for-2015-5.html